Physician profile
Mark Lejsek
NPI 1891016010
$10,450.81
in general payments reported to CMS, 2019-2025
26 companies · $2,240 in 2025
The $2,240 reported for 2025 was more than what 94% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $330 · 2022: $2,439 · 2023: $2,853 · 2024: $2,589 · 2025: $2,240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,674 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,673.66 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $1,585.31 | 2022-2025 | Lybalvi, Aristada |
| Abbvie INC. | $1,494.33 | 2021-2025 | |
| Corium, LLC | $1,368.00 | 2022-2025 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,260.72 | 2021-2025 | Caplyta |
| Neos Therapeutics, LP | $1,089.47 | 2021-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Tris Pharma INC | $829.34 | 2022-2025 | Dyanavel Xr, Onyda Xr |
| Sunovion Pharmaceuticals INC. | $680.52 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $439.22 | 2022-2024 | Jornay Pm |
| Teva Pharmaceuticals USA, INC. | $230.23 | 2022-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Neurocrine Biosciences, INC. | $192.66 | 2022-2025 | Ingrezza |
| Noven Therapeutics, LLC | $188.95 | 2022-2025 | Xelstrym, Secuado |
| Bausch Health US, LLC | $170.01 | 2022-2025 | Aplenzin |
| Supernus Pharmaceuticals, INC. | $160.73 | 2022-2025 | Qelbree, Qelbree |
| Otsuka America Pharmaceutical, INC. | $147.58 | 2022-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| E.R. Squibb & Sons, L.L.C. | $114.05 | 2024-2025 | Cobenfy |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $112.30 | 2022-2024 | Trintellix |
| Axsome Therapeutics, INC. | $112.12 | 2022-2025 | Sunosi, Auvelity |
| Janssen Pharmaceuticals, INC | $65.98 | 2021-2025 | Spravato |
| Vanda Pharmaceuticals INC. | $58.49 | 2022-2025 | Fanapt |
| Almatica Pharma LLC | $36.42 | 2023-2025 | Loreev Xr |
| Idorsia Pharmaceuticals US INC | $28.13 | 2023-2024 | Quviviq |
| Biogen, INC. | $22.17 | 2024 | |
| Eisai INC. | $18.93 | 2022 | |
| Alfasigma USA, INC. | $18.59 | 2022 | |
| Lundbeck LLC | $13.43 | 2024 | Rexulti |
| Validus Pharmaceuticals LLC | $13.13 | 2023 | Equetro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Lejsek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.